Evidence map›Paper›PMID 32737354›Full record

Trial reportScientific reports2020

Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for 'leaky-gut' in inflammatory bowel disease.

Valerie C Wasinger, Kenneth Lu, Yunki Y Yau, Justin Nash, Jess Lee, Jeff Chang, Sudarshan Paramsothy, Nadeem O Kaakoush, Hazel M Mitchell, Rupert W L Leong

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Serum proteome of dogs with chronic enteropathy.Journal of veterinary internal medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Valerie C WasingerBioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, NSW, Australia. v.wasinger@unsw.edu.au.
Kenneth LuSchool of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia.
Yunki Y YauSchool of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia.
Justin NashBioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, NSW, Australia.
Jess LeeSchool of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia.
Jeff ChangGastroenterology Department, Concord Repatriation General Hospital, Hospital Rd, Concord, NSW, Australia.
Sudarshan ParamsothyGastroenterology Department, Concord Repatriation General Hospital, Hospital Rd, Concord, NSW, Australia.
Nadeem O KaakoushSchool of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia.
Hazel M MitchellSchool of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, Australia.
Rupert W L LeongSchool of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia.
UNSW Sydney · AUConcord Repatriation General Hospital · AUBankstown Lidcombe Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial barrier injury allows contaminants to cross-over into the blood stream and trigger an inflammatory response, contributing to inflammatory bowel disease (IBD). Currently there is no single test that can reliably diagnose intestinal mucosal barrier function or measure impaired epithelial cell integrity associated with increasing permeability. Here, we assess the association between serum proteins and small intestinal permeability as detected by confocal laser endomicroscopy (CLE); in particular the known IBD marker-secreted phosphoprotein 24 (SPP24) and its binding partners; and use developed monoclonal antibodies to assess the role of SPP24 in mucosal healing. Sera were obtained from 28 IBD patients and non-IBD controls undergoing CLE with scores ranging from low to high permeability, as well as active ulcerative colitis from 53 patients undergoing fecal microbiota transplant therapy (FMT). Higher permeability associated with altered lipid metabolism, heightened innate immune response and junctional protein signalling in UC patients. A correlation between increasing leak and SPP24 peptide was observed. There is a strong indication of the novel role of SPP24 in gut barrier dysfunction particularly in ulcerative colitis. Its correlation to the established CLE for monitoring permeability has the potential to provide a blood based parallel to monitor and guide therapy more readily across a broad spectrum of illnesses for which 'leak' dominates the pathology.

Indexed as

EndocytosisLipid MetabolismSignal TransductionAdolescentAdultAgedBiomarkersColitis, UlcerativeFecal Microbiota TransplantationFemaleHumansIntestinal MucosaMaleMiddle AgedPhosphoproteinsBiomarkersPhosphoproteinssecreted phosphoprotein 24

Identifiers

PMID32737354
PMCPMC7395150
OpenAlexW3046538587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.